Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S9QA
|
|||
| Former ID |
DNCL001898
|
|||
| Drug Name |
Ivabradine
|
|||
| Synonyms |
Ivabradine; 155974-00-8; Procoralan; Corlanor; Corlentor; UNII-3H48L0LPZQ; S 16257; S-16257; S-16257-2; S 16257-2; 3H48L0LPZQ; CHEMBL471737; CHEBI:85966; C27H36N2O5; 7,8-Dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one; S-16260-2; s16257; (S)-3-(3-(((3,4-Dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one; Ivabradine [INN]
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Angina pectoris [ICD-11: BA40; ICD-9: 413] | Approved | [1], [2], [3] | |
| Company |
Servier
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H36N2O5
|
|||
| Canonical SMILES |
CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)CC3CC4=CC(=C(C=C34)OC)OC
|
|||
| InChI |
1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1
|
|||
| InChIKey |
ACRHBAYQBXXRTO-OAQYLSRUSA-N
|
|||
| CAS Number |
CAS 155974-00-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10243263, 14809487, 14858507, 29311012, 49831170, 49877976, 50581724, 51091504, 57344340, 103585166, 104378744, 123106107, 126616788, 126666980, 127346366, 134222945, 135259365, 135650438, 137117417, 139529350, 152035913, 162187482, 164833119, 175267572, 180100905, 198965224, 223554829, 223660350, 224408028, 226412169, 242761946, 251916692, 251917931, 252150276
|
|||
| ChEBI ID |
CHEBI:85966
|
|||
| ADReCS Drug ID | BADD_D01218 ; BADD_D01219 | |||
| SuperDrug ATC ID |
C01EB17
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hyperpolarization cyclic nucleotide-gated channel (HCN) | Target Info | Inhibitor | [4] |
| Sinus node I(f) channel (SA node IfC) | Target Info | Modulator | [5] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2357). | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | ClinicalTrials.gov (NCT01373619) Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine. U.S. National Institutes of Health. | |||
| REF 4 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
| REF 5 | Ivabradine - the first selective sinus node If channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006 February; 60(2): 222-228. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.